Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsQualChoice Palbociclib Prior Auth Coverage | OpenP…
    Ask Trek AI about this page
    ModifiedQualChoicePolicy AR.QC.HIM.PA.173

    Palbociclib (Ibrance) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for QualChoice Policy AR.QC.HIM.PA.173 alerts

    Get alerted when Policy AR.QC.HIM.PA.173 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    QualChoice Commercial coverage and prior authorization for palbociclib (Ibrance) and generic palbociclib in adults with specified breast cancers, soft tissue sarcoma, uterine neoplasms, and other requested indications.

    Policy Summary
    PayerQualChoice
    PolicyPalbociclib (Ibrance) Coverage and Prior Authorization
    Policy CodePolicy AR.QC.HIM.PA.173
    Change TypeModified
    Effective DateJan 1, 202745d
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation demonstrating that all applicable initial or continued-therapy criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    The policy was adapted from HIM.PA.173 and maintains redirection to Kisqali and Verzenio for breast cancer.

    12 monthsApproval duration
    125 mg/dayMaximum standard dose
    30 daysMinimum prior treatment for continuation
    ≥75 mg/dayMinimum breast cancer continuation dose
    Stage 0-III

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Excluded adjuvant setting

    Coverage Criteria

    Initial therapy — breast cancer

    Covered for breast cancer when ALL of the following are met, including ONE applicable treatment pathway.

    Breast cancer initial approval

    • General criteria

      • Diagnosis and disease status

        • Diagnosis of breast cancer.
        • Disease is hormone receptor-positive, meaning estrogen receptor and/or progesterone receptor positive.
        • Disease is advanced, including locally advanced, recurrent, or metastatic.
      • Prescribed by or in consultation with an oncologist.
      • Member is age 18 years or older.Age ≥18 years
    • Applicable prerequisite pathway

      • Member uses Kisqali and Verzenio, unless clinically significant adverse effects are experienced or both agents are contraindicated.
      • The request is for treatment associated with cancer in a state with regulations against step therapy in the applicable oncology setting.

        State-specific protections are listed in Appendix E.

    • Applicable treatment regimen

      • HER2-negative disease: aromatase-inhibitor pathway

        • Ibrance is used in combination with an aromatase inhibitor, such as letrozole, anastrozole, or exemestane, as initial endocrine-based therapy.
        • For a male member, the regimen includes an agent that suppresses testicular steroidogenesis, such as a gonadotropin-releasing hormone agonist.
      • For HER2-negative disease, Ibrance is used in combination with fulvestrant.
      • HER2-negative disease: Revtorpyk pathway

        • Ibrance is used in combination with fulvestrant and Revtorpyk.
        • Disease has progressed on or after an endocrine-based therapy regimen in the metastatic setting.
    • Additional requirements

      • If the member is a premenopausal or perimenopausal female, the member has undergone ovarian ablation or is receiving ovarian suppression.
      • Member has not previously experienced disease progression while receiving CDK4/6 inhibitor therapy.
      • Ibrance is not prescribed concurrently with another CDK4/6 inhibitor, including Verzenio or Kisqali.
      • For a brand Ibrance request, generic palbociclib is used when available unless it is contraindicated or causes clinically significant adverse effects.
      • Dose requirement

        • Dose does not exceed 125 mg per day and 1 capsule or 1 tablet per day on Days 1 through 21 of a 28-day cycle.≤125 mg/day; ≤1 capsule or tablet/day on Days 1-21 of a 28-day cycle

    Initial therapy — soft tissue sarcoma

    Covered for soft tissue sarcoma when ALL of the following are met.

    Soft tissue sarcoma

    • Diagnosis is well-differentiated or dedifferentiated liposarcoma.
    • Prescribed by or in consultation with an oncologist.
    • Member is age 18 years or older.Age ≥18 years
    • Disease is unresectable.
    • Ibrance is prescribed as a single agent.

    Initial therapy — uterine neoplasms

    Covered for uterine neoplasms when ALL of the following are met.

    Uterine neoplasms

    • Qualifying diagnosis and regimen

      • Diagnosis is endometrial carcinoma and Ibrance is used in combination with letrozole.
      • Diagnosis is uterine sarcoma and Ibrance is used as a single agent.
    • Prescribed by or in consultation with an oncologist.
    • Member is age 18 years or older.Age ≥18 years

    Other diagnoses and indications

    Other diagnoses and indications follow ONE of the following pathways.

    Other diagnosis or indication pathway

    • Recent label change pathway

      • The drug underwent a label change within the last 6 months that is not yet reflected in this policy, and the drug is on the formulary; refer to the applicable formulary no-coverage-criteria policy, HIM.PA.33.
      • The drug underwent a label change within the last 6 months that is not yet reflected in this policy, and the drug is not on the formulary; refer to the applicable nonformulary policy, HIM.PA.103.
    • The requested use is not specifically listed under diagnoses or indications for which coverage is not authorized, the recent-label-change pathway does not apply, and the request is referred to the applicable off-label use policy, HIM.PA.154.

    Continued therapy — all indications

    Continued therapy for all indications requires ALL of the following.

    Continuation therapy

    • Current therapy requirement

      • Member is currently receiving the medication through the Centene benefit.
      • Documentation supports that the member is currently receiving Ibrance for a covered indication and has received it for at least 30 days.≥30 days
    • Member is responding positively to therapy.
    • Ibrance is not prescribed concurrently with another CDK4/6 inhibitor, including Verzenio or Kisqali.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless the provider submits sufficient documentation of efficacy and safety under the applicable off-label use policy, HIM.PA.154, or applicable evidence-of-coverage documents.

    Palbociclib is not authorized for adjuvant therapy in early-stage stage 0-III breast cancer.

    Palbociclib must not be used concurrently with another CDK4/6 inhibitor, including Verzenio or Kisqali. This restriction applies to both initial and continued therapy.

    Dose and Treatment Parameters

    Standard palbociclib dose
    Maximum daily doseNot more than 125 mg per day
    Daily quantity1 capsule or 1 tablet per day
    Cycle scheduleDays 1-21 of a 28-day cycle
    Breast cancer continued-therapy dose
    Minimum daily doseAt least 75 mg per day
    Applies toContinued therapy for breast cancer
    Coverage contextThe member must be responding positively to therapy and meet the continued-therapy criteria

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for initial and continued coverage of palbociclib. The provider must submit documentation supporting that the member meets all applicable approval criteria.

    • Applies to all covered indications and continuation requests.
    • For continued therapy, document current use through the Centene benefit or at least 30 days of therapy for a covered indication, along with positive response.
    Note

    12-Month Approval Period

    Approved initial and continued-therapy requests are authorized for a 12-month period when the applicable indication and clinical criteria are satisfied.

    • Applies to listed breast cancer, soft tissue sarcoma, and uterine neoplasm indications.
    • The 12-month period applies to both initial approval and continued therapy.

    Medication Background

    Palbociclib (Ibrance) is a cyclin-dependent kinase 4 and 6 inhibitor used with endocrine and targeted therapies for selected adult hormone receptor-positive breast cancers, including specified advanced, recurrent, locally advanced, or metastatic disease. The policy also addresses selected uses in soft tissue sarcoma and uterine neoplasms.

    Clinical Definitions

    Palbociclib
    DrugPalbociclib (Ibrance)
    Drug classCyclin-dependent kinase 4/6 inhibitor
    DefinitionAn inhibitor of cyclin-dependent kinases 4 and 6 (CDK 4/6)
    HR-positive
    AbbreviationHR-positive
    MeaningHormone receptor status is positive
    Positive markersEstrogen receptor (ER) and/or progesterone receptor (PR) is positive

    Initial Therapy Criteria

    Initial therapy — soft tissue sarcoma

    Initial soft tissue sarcoma therapy requires ALL of the following.

    Liposarcoma

    • Diagnosis is well-differentiated or dedifferentiated liposarcoma.
    • Disease is unresectable.
    • Member is age 18 years or older.Age ≥18 years
    • Prescribed by or in consultation with an oncologist.

    Continuation Therapy Criteria

    Continuation therapy

    Continued therapy is covered when ALL continuation criteria are met.

    Continuation criteria

    • Current therapy requirement

      • Member is currently receiving the medication through the Centene benefit.
      • Documentation supports current Ibrance use for a covered indication for at least 30 days.≥30 days
    • Member is responding positively to therapy.
    • Ibrance is not used concurrently with another CDK4/6 inhibitor.

    Preferred Therapy Sequence

    StepRequirementExceptions
    1For applicable breast cancer requests, use Kisqali and Verzenio before Ibrance.The requirement does not apply when clinically significant adverse effects are experienced, both agents are contraindicated, or a state regulation prohibits step therapy in the applicable oncology setting. Prior authorization may be required for Kisqali and Verzenio.
    StepRequirementExceptions
    2For brand Ibrance requests, use generic palbociclib when available.The requirement does not apply when generic palbociclib is contraindicated or causes clinically significant adverse effects.
    Applies toPolicy direction
    Breast cancerThe policy maintains redirection to Kisqali and Verzenio as an operational alternative-therapy consideration.

    Palbociclib Quantity Limits

    Palbociclib/Ibrance quantity limit
    Maximum daily dose125 mg per day
    Maximum quantity1 capsule or 1 tablet per day
    Covered daysDays 1-21
    Cycle28-day cycle
    Policy Summary
    PayerQualChoice
    PolicyPalbociclib (Ibrance) Coverage and Prior Authorization
    Policy CodePolicy AR.QC.HIM.PA.173
    Change TypeModified
    Effective DateJan 1, 202745d
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit documentation demonstrating that all applicable initial or continued-therapy criteria are met.
    SourceLink
    On This Page
    Coverage CriteriaDose and Treatment ParametersAuthorization and Documentation RequirementsMedication BackgroundClinical DefinitionsInitial Therapy CriteriaContinuation Therapy CriteriaPreferred Therapy SequencePalbociclib Quantity Limits
  1. HER2-negative disease: PIK3CA-mutated pathway

    • Ibrance is used in combination with inavolisib and fulvestrant.
    • Disease is positive for a PIK3CA mutation.
    • Disease progressed or recurred on or after adjuvant endocrine therapy.
    • For a male member, the regimen includes an agent that suppresses testicular steroidogenesis, such as a gonadotropin-releasing hormone agonist.
  2. HER2-positive disease pathway

    • Ibrance is used in combination with trastuzumab and endocrine therapy, such as letrozole, anastrozole, exemestane, or fulvestrant.
    • Ibrance is used for maintenance treatment following induction therapy.
    • For a male member, the regimen includes an agent that suppresses testicular steroidogenesis, such as a gonadotropin-releasing hormone agonist.
  3. Requested dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  4. The prescribed regimen is FDA-approved or recommended by NCCN where specified.
  5. Ibrance is not prescribed concurrently with another CDK4/6 inhibitor, including Verzenio or Kisqali.
  6. For a brand Ibrance request, generic palbociclib is used when available unless it is contraindicated or causes clinically significant adverse effects.
  7. Dose requirement

    • Dose is within the FDA maximum limit for any FDA-approved indication.
    • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  8. The prescribed regimen is FDA-approved or recommended by NCCN where specified.
  9. Ibrance is not prescribed concurrently with another CDK4/6 inhibitor, including Verzenio or Kisqali.
  10. For a brand Ibrance request, generic palbociclib is used when available unless it is contraindicated or causes clinically significant adverse effects.
  11. Dose requirement

    • Dose is within the FDA maximum limit for any FDA-approved indication.
    • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  12. For breast cancer, the dose is at least 75 mg per day.≥75 mg/day for breast cancer
  13. For a brand Ibrance request, generic palbociclib is used when available unless it is contraindicated or causes clinically significant adverse effects.
  14. Dose-increase requirement

    • The new dose does not exceed 125 mg per day and 1 capsule or 1 tablet per day on Days 1 through 21 of a 28-day cycle.≤125 mg/day; ≤1 capsule or tablet/day on Days 1-21 of a 28-day cycle
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  15. The prescribed regimen is FDA-approved or recommended by NCCN where specified.
  16. Prior treatment duration for continuation
    Minimum treatment durationAt least 30 days
    Applies toContinued therapy for all indications
    DocumentationDocumentation must support current Ibrance use for a covered indication
    Note

    Palbociclib Approval Duration

    When palbociclib coverage is approved, the approval duration is 12 months.

    • Continuation remains subject to response, dosing, concurrent-therapy, and other applicable criteria.
    Step Therapy

    Preferred CDK4/6 Prerequisite

    For qualifying breast cancer requests, the member must use Kisqali and Verzenio unless clinically significant adverse effects are experienced or both agents are contraindicated. State-specific oncology step-therapy protections may provide an exception.

    • Prior authorization may be required for Kisqali and Verzenio.
    • Applicable protections include listed states and qualifying advanced or metastatic cancer circumstances in Appendix E.
    Step Therapy

    Generic Palbociclib Preference

    For brand Ibrance requests, generic palbociclib must be used when available unless it is contraindicated or the member has experienced clinically significant adverse effects.

    • The generic preference applies to breast cancer, soft tissue sarcoma, uterine neoplasm, and continuation requests.
    • Document the contraindication or clinically significant intolerance when requesting brand Ibrance.
    Step Therapy

    Alternative CDK4/6 Redirection

    Redirect qualifying requests to the preferred alternative CDK4/6 inhibitors, Kisqali or Verzenio, before approving palbociclib, unless a documented exception applies.

    • Redirection does not replace review of medical necessity or clinical appropriateness.
    • Apply documented contraindication, clinically significant adverse-effect, or applicable state-law exceptions.
    Documentation Required

    Clinical Records Required

    Submit clinical records supporting the request, including office chart notes, laboratory results, and other relevant clinical information.

    • Records must support that the member has met all approval criteria.
    Documentation Required

    Evidence for Off-Label Use or Dosing

    For off-label use or dosing outside standard limits, the prescriber must submit supporting evidence from practice guidelines or peer-reviewed literature.

    • The prescribed regimen must be FDA-approved or recommended by NCCN when required by the applicable criterion.
    • Evidence must support the relevant off-label indication or dose.
    Documentation Required

    Disease and Treatment History

    Document the member’s disease and treatment history, including diagnosis, age, disease characteristics, prescriber or oncology consultation, prior treatment, and current response when applicable.

    • Breast cancer documentation includes HR status, HER2 status, disease stage or recurrence, and applicable treatment combinations.
    • Document prior endocrine therapy, induction therapy, ovarian ablation or suppression, and current therapy when relevant.
    • For continuation, document at least 30 days of treatment and positive response.
    Denial Risk

    Breast Cancer Criteria Not Met

    Deny breast cancer requests that do not satisfy all required criteria, including the diagnosis, oncology involvement, age, HR-positive advanced or recurrent/metastatic disease, applicable treatment regimen, and other required conditions.

    • Also verify required ovarian ablation or suppression for premenopausal or perimenopausal females.
    • Do not approve when the member has progressed on a CDK4/6 inhibitor or is receiving another CDK4/6 inhibitor concurrently.
    Denial Risk

    Off-Label Oncology Criteria Not Met

    Deny off-label soft tissue sarcoma or uterine neoplasm requests that fail the indication-specific criteria.

    • Soft tissue sarcoma requires well-differentiated or dedifferentiated liposarcoma, unresectable disease, oncology involvement, age 18 or older, and single-agent use.
    • Uterine neoplasm requests require an eligible endometrial carcinoma or uterine sarcoma diagnosis and the specified combination or single-agent regimen.
    • Verify that palbociclib is not combined with another CDK4/6 inhibitor.
    Denial Risk

    Unsupported Dose or Regimen

    Do not approve an unsupported dose or regimen. The prescribed dose must remain within the applicable FDA limits or be supported by NCCN, practice guidelines, or peer-reviewed literature.

    • Standard breast cancer dosing must not exceed 125 mg per day and one capsule or tablet per day on Days 1–21 of a 28-day cycle.
    • For dose increases, document that the new dose meets the same limits or is supported for the relevant off-label use.
    • For soft tissue sarcoma and uterine neoplasm, the dose must be within the FDA maximum for any FDA-approved indication or have supporting evidence.

    Unsupported block type: denial_risk事列UTION?

    Step Therapy

    Step-Therapy Requirement

    Require preferred Kisqali and Verzenio therapy for qualifying breast cancer requests before palbociclib approval, subject to documented contraindication, clinically significant adverse effects, or applicable state regulations against step therapy.

    • Prior authorization may be required for the preferred agents.
    • State exceptions are limited to the cancer stages, indications, and circumstances identified in Appendix E.
    Denial Risk

    Progression on Prior CDK4/6 Therapy

    Do not approve retreatment with another CDK4/6 inhibitor-containing regimen when the disease progressed during prior CDK4/6 inhibitor therapy; the policy notes that supporting data are lacking.

    • This is distinct from the requirement that palbociclib not be prescribed concurrently with Verzenio or Kisqali.
    HER2-negative
    AbbreviationHER2-negative
    Full termHuman epidermal growth factor receptor 2 negative
    StatusHuman epidermal growth factor receptor 2 status is negative
    ER
    AbbreviationER
    Full termEstrogen receptor
    Role in HR statusER positivity qualifies as hormone receptor-positive status
    PR
    AbbreviationPR
    Full termProgesterone receptor
    Role in HR statusPR positivity qualifies as hormone receptor-positive status
    Ovarian ablation or suppression
    PurposeReduce ovarian estrogen production
    Ovarian suppressionUses luteinizing hormone-releasing hormone (LHRH) agonists
    Ovarian ablationMay be achieved by surgical oophorectomy or ovarian irradiation
    Ovarian ablation
    DefinitionOvarian ablation is the elimination of ovarian function to reduce ovarian estrogen production
    Surgical methodSurgical oophorectomy
    Radiation methodOvarian irradiation
    Ovarian suppression
    DefinitionOvarian suppression reduces ovarian estrogen production
    Medication classLuteinizing hormone-releasing hormone (LHRH) agonists
    MechanismSuppresses pituitary luteinizing hormone and follicle-stimulating hormone release, reducing ovarian estrogen production
    ExamplesGoserelin and leuprolide
    Ibrance is prescribed as a single agent.
  17. Ibrance is not used concurrently with another CDK4/6 inhibitor.
  18. Generic palbociclib is used when available unless contraindicated or associated with clinically significant adverse effects.
  19. Dose requirement

    • Dose is within the FDA maximum limit for any FDA-approved indication.
    • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  20. The prescribed regimen is FDA-approved or recommended by NCCN where specified.
  21. Initial therapy — uterine neoplasms

    Initial uterine neoplasm therapy requires ALL of the following.

    Uterine neoplasms

    • Qualifying diagnosis and regimen

      • Endometrial carcinoma treated in combination with letrozole.
      • Uterine sarcoma treated with Ibrance as a single agent.
    • Member is age 18 years or older.Age ≥18 years
    • Prescribed by or in consultation with an oncologist.
    • Ibrance is not used concurrently with another CDK4/6 inhibitor.
    • Generic palbociclib is used when available unless contraindicated or associated with clinically significant adverse effects.
    • Dose requirement

      • Dose is within the FDA maximum limit for any FDA-approved indication.
      • Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  22. For breast cancer, the dose is at least 75 mg per day.≥75 mg/day
  23. Generic palbociclib is used when available unless contraindicated or associated with clinically significant adverse effects.
  24. Dose-increase requirement

    • The new dose does not exceed 125 mg per day and 1 capsule or 1 tablet per day on Days 1 through 21 of a 28-day cycle.≤125 mg/day on Days 1-21 of a 28-day cycle
    • The new dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use, with supporting evidence submitted by the prescriber.
  25. The prescribed regimen is FDA-approved or recommended by NCCN where specified.